India has the second highest burden of thyroid disease in the world. The Indian Thyroid Society estimates that 42 million Indians suffer from thyroid disorders, with hypothyroidism being the dominant condition. Yet the management of even basic hypothyroidism is riddled with errors in Indian practice: wrong TSH targets, inappropriate T3/T4 combinations, over-treatment of subclinical disease, and missed thyroid nodule malignancy. In 2026, search data from Indian medical platforms confirms that thyroid-related queries — especially around TSH targets in pregnancy, Hashimoto's thyroiditis management, and thyroid nodule FNAC indications — are among the most searched clinical topics by Indian doctors. This guide provides sharp, evidence-based answers to the thyroid questions Indian doctors are actually searching for. TSH Targets in 2026: What Are the Right Numbers? The appropriate TSH target depends entirely on the clinical context. One of the most common errors in Indian practice is applying a single TSH target to all patients. Here is the evidence-based framework: Non-pregnant adults on levothyroxine for hypothyroidism: TSH target 0.5–2.5 mIU/L (not 0.5–5.0 — the upper end of the 'normal' range is too broad for treated patients) Elderly patients (≥65 years): TSH target 1–4 mIU/L. Over-suppression increases atrial fibrillation and fracture risk. Pregnancy — First trimester: TSH <2.5 mIU/L; Second and third trimesters: TSH <3.0 mIU/L. The 2017 ATA guidelines reduced the upper limit, and this is now the standard for all Indian reproductive medicine practices. Post-thyroidectomy for low-risk differentiated thyroid cancer: TSH 0.5–2.0 mIU/L (mild suppression no longer routinely recommended for all) Post-thyroidectomy for high-risk differentiated thyroid cancer: TSH <0.1 mIU/L for the initial 5 years, then reassess Practical tip: When a patient on levothyroxine has symptoms but 'normal' TSH on a lab report, check whether the lab reference range used is 0.4–4.5 or 0.4–5.5. Many Indian labs still use older wider ranges, leading to under-treatment of symptomatic hypothyroidism. Hypothyroidism: Diagnosis, Levothyroxine Dosing, and Common Errors Overt hypothyroidism (TSH >10 mIU/L with low fT4) always requires treatment. The starting levothyroxine dose depends on age and cardiac status: Young, healthy adults: Full replacement dose from start — 1.6 mcg/kg/day Elderly or known coronary artery disease: Start low at 12.5–25 mcg/day and titrate slowly over 6–8 weeks to avoid precipitating angina or arrhythmia Pregnancy with overt hypothyroidism: Start at full replacement dose immediately — do not titrate slowly. Delay is harmful to fetal neurodevelopment. Common errors to avoid: prescribing combination T3+T4 therapy routinely (evidence only supports this in specific cases), checking TSH less than 6 weeks after a dose change (TSH has a half-life of 7 days and takes 6 weeks to equilibrate), and prescribing levothyroxine at the wrong time (it must be taken on an empty stomach, 30–60 minutes before food or other medications). Subclinical Hypothyroidism: When to Treat and When to Watch Subclinical hypothyroidism (SCH) is defined as elevated TSH with normal fT4. This is the area of greatest clinical controversy — and also one of the most over-treated conditions in Indian practice. The current evidence-based guidance: TSH 4.5–10 mIU/L: Treat if symptomatic, pregnant, trying to conceive, or aged <65. Do not treat routinely in asymptomatic elderly patients — the TRUST trial showed no benefit. TSH >10 mIU/L: Treat in all age groups. The risk of progression to overt hypothyroidism is high (4–8% per year). Repeat TSH before treating: At least 2 elevated TSH readings 3–6 months apart, as transient TSH elevations are common after illness, stress, and certain medications. Hashimoto's Thyroiditis: What Indian Doctors Need to Know Hashimoto's thyroiditis (autoimmune thyroiditis) is the most common cause of hypothyroidism in India. It is characterised by elevated anti-TPO antibodies (anti-thyroid peroxidase), a heterogeneous thyroid on ultrasound, and a slow progression to hypothyroidism. Several important clinical points: Anti-TPO positivity alone without elevated TSH does not require treatment. The annual risk of developing overt hypothyroidism is 2–4% per year — monitor TSH annually. Selenium supplementation (200 mcg/day) reduces anti-TPO titres and improves symptoms in Hashimoto's — this is increasingly incorporated in Indian endocrinology practice, though it does not affect TSH or fT4. Hashimoto's encephalopathy is rare but treatable — suspect in patients with cognitive changes, seizures, or psychiatric symptoms with high anti-TPO levels. It responds to steroids. The association between Hashimoto's and other autoimmune conditions (Type 1 diabetes, coeliac disease, pernicious anaemia, Sjogren's, SLE) is important in Indian female patients. Consider screening for these conditions. Thyroid Nodule Workup: When to Do FNAC and When to Refer Thyroid nodules are found in up to 67% of the population on ultrasound. The vast majority are benign, but the clinical imperative is to identify the 5–15% that are malignant. The TIRADS (Thyroid Imaging Reporting and Data System) scoring system is now the standard for nodule risk stratification in India: TIRADS 1–3 (benign/likely benign): Ultrasound follow-up at 12–24 months, no FNAC needed unless symptomatic or rapidly growing TIRADS 4A (low suspicion): FNAC if ≥1.5 cm TIRADS 4B/4C (intermediate/high suspicion): FNAC if ≥1 cm TIRADS 5 (highly suspicious for malignancy — microcalcifications, irregular margins, taller than wide, hypoechoic): FNAC if ≥0.5 cm; surgical referral if features are highly concerning regardless of size Always check TSH before FNAC: A suppressed TSH with a nodule suggests a functioning (hot) nodule, which is almost always benign. Proceed to a thyroid scan rather than FNAC in this scenario. Hyperthyroidism in India: Graves' Disease vs Toxic Nodular Disease Graves' disease is the most common cause of hyperthyroidism in younger Indian patients, while toxic multinodular goitre predominates in older patients and those from iodine-deficient regions. Distinguishing between these is clinically important as management differs: Graves' disease: Anti-TSH receptor antibodies (TRAb) positive, diffuse goitre, possible ophthalmopathy. First-line: Carbimazole or propylthiouracil (PTU preferred in first trimester pregnancy). Aim for remission at 12–18 months; if relapse, consider radioiodine or thyroidectomy. Toxic nodular goitre: TRAb negative, nodular or heterogeneous gland on scan. First-line in India is often carbimazole for symptomatic control, followed by radioiodine or surgery for definitive treatment as remission is rare with ATDs alone. Thyroid storm: A medical emergency. Treat with high-dose PTU (blocks T4 to T3 conversion), propranolol, iodine solution (1 hour after PTU), hydrocortisone, and supportive care. Admit to ICU. Thyroid in Pregnancy: The 10 Things Every Indian Doctor Must Get Right Screen all pregnant women at first antenatal visit with TSH. India has high rates of both iodine deficiency and Hashimoto's thyroiditis. TSH >2.5 mIU/L in the first trimester requires immediate levothyroxine initiation, not watchful waiting. Increase levothyroxine dose by 25–30% immediately on confirmation of pregnancy in known hypothyroid patients. Monitor TSH every 4 weeks in the first trimester and every 6 weeks thereafter. PTU is preferred over carbimazole in the first trimester (lower teratogenicity risk). Switch to carbimazole after 16 weeks. Frequently Asked Questions: Thyroid Disorders for Indian Doctors Should I add T3 (liothyronine) to levothyroxine therapy for hypothyroidism? Combination T3+T4 therapy is not recommended as routine first-line treatment. The 2019 ATA guidelines acknowledge that a subset of patients on adequate levothyroxine who remain symptomatic may benefit from a trial of combination therapy, but this should be done by an endocrinologist. The common Indian practice of prescribing T3+T4 combinations to all hypothyroid patients is not evidence-based and may cause harm through T3-induced cardiac toxicity. Can levothyroxine cause hair loss? Both hypothyroidism itself and over-treatment with levothyroxine can cause hair loss (telogen effluvium). If a patient reports hair loss after starting levothyroxine, check TSH. Over-suppression is a common cause. Hair loss from hypothyroidism typically takes 6– months to recover after adequate treatment — counsel patients on this expected timeline. Is a TSH of 6 mIU/L dangerous in a non-pregnant adult? Not necessarily dangerous, but clinically significant. TSH between 4.5–10 is subclinical hypothyroidism. Whether to treat depends on symptoms, age, anti-TPO status, and cardiovascular risk. A single TSH reading should not trigger immediate treatment — confirm with a repeat 3 months later. If the patient is symptomatic or anti-TPO positive with TSH >6, a treatment trial is reasonable. What is the best time to take levothyroxine? Levothyroxine should be taken on an empty stomach, 30–60 minutes before breakfast, with water only. Calcium, iron, antacids, PPIs, and certain foods (soya, high-fibre) significantly reduce absorption. In Indian patients who struggle with this routine, bedtime dosing (at least 3 hours after the last meal) is a clinically validated alternative with equivalent efficacy. Is thyroid disease hereditary? Yes, there is a strong genetic component. First-degree relatives of patients with Hashimoto's thyroiditis or Graves' disease have a 3–5x higher risk of developing thyroid autoimmunity. In India, this is often seen as thyroid disease clustering in families across generations. Counsel patients to inform their family members, and offer TSH screening to symptomatic relatives. Can hypothyroidism cause weight gain? Overt hypothyroidism typically causes modest weight gain (3–5 kg) due to reduced metabolic rate and fluid retention. However, treating hypothyroidism rarely produces significant weight loss — most patients lose only the fluid component (1–2 kg). Patients who expect dramatic weight loss after starting levothyroxine should be counselled that thyroid normalisation addresses metabolic dysfunction but is not a primary weight-loss intervention. What is the significance of thyroid peroxidase (TPO) antibodies? Elevated anti-TPO antibodies indicate thyroid autoimmunity (Hashimoto's thyroiditis). In a patient with normal TSH and no symptoms, positive anti-TPO means monitoring annually — not treatment. In a patient trying to conceive, positive anti-TPO with TSH >2.5 mIU/L is a strong indication for levothyroxine. In pregnancy, high anti-TPO is associated with increased risk of miscarriage and postpartum thyroiditis. When should a thyroid nodule patient be referred to a surgeon? Refer for surgical evaluation when: FNAC shows Bethesda category IV (follicular neoplasm), V (suspicious for malignancy), or VI (malignant); when a nodule causes compressive symptoms (dysphagia, voice change, stridor); when there is rapid growth >20% in volume over 6 months; or when the nodule is >4 cm regardless of FNAC result due to false negative rate. How DocTrust Supports Better Thyroid Patient Management in Indian Clinics Thyroid disease is a long-term condition requiring TSH monitoring at regular intervals — every 6 weeks when titrating doses, every 6 months when stable. In a busy Indian clinic with hundreds of patients, tracking who needs their next TSH check and who hasn't followed up is nearly impossible manually. DocTrust's AI-powered clinic management platform automates this: scheduled follow-up reminders via WhatsApp, digital prescription records that flag when a patient's last lab check was done, and structured OPD notes that ensure every thyroid patient leaves your clinic with a clear next-step plan. For patients on lifelong levothyroxine, DocTrust's automated refill reminder system dramatically improves adherence — addressing one of the most common reasons for poorly controlled hypothyroidism in India. Join India's leading clinics in delivering structured, data-driven chronic care. Book your free DocTrust demo at www.doctrust.in today.